News | October 23, 2025
Ipsen to acquire ImCheck Therapeutics to strengthen oncology pipeline
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Expanding US operations to address the increased demand for API development and manufacturing
This new facility strengthens Latin America as a collaborative hub
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Subscribe To Our Newsletter & Stay Updated
